News for Medicenna Therapeutics Corp Stock (MDNAF)

Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewsWire • 12/13/24

Medicenna Provides Clinical Update and Announces First Complete Responder in MDNA11 and KEYTRUDA® (pembrolizumab) Combination Dose Escalation Arm of the ABILITY-1 Study

GlobeNewsWire • 12/05/24

Updated MDNA11 Monotherapy and Combination Clinical Data from the Ongoing Phase 1/2 ABILITY-1 Study to be Presented at the 2024 Immunotherapy Bridge Conference

GlobeNewsWire • 11/27/24

Medicenna Presents Preclinical Data on MDNA11 and Bizaxofusp at the 2024 Annual Meeting of the Society for Neuro-Oncology (SNO)

GlobeNewsWire • 11/25/24

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

GlobeNewsWire • 11/15/24

Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)

GlobeNewsWire • 11/13/24

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewsWire • 11/08/24

Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewsWire • 10/04/24

Medicenna Announces Results of Annual Meeting of Shareholders

GlobeNewsWire • 09/26/24

Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference

GlobeNewsWire • 09/09/24

Medicenna Strengthens Board of Directors with Appointment of Karim Lalji

GlobeNewsWire • 08/15/24

Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy

GlobeNewsWire • 08/01/24

Medicenna's MDNA11 And Bizaxofusp Show Strong Potential Despite Delisting

Seeking Alpha • 07/22/24

Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights

GlobeNewsWire • 06/27/24

Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe

GlobeNewsWire • 06/26/24

Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting

GlobeNewsWire • 06/03/24

Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum

GlobeNewsWire • 05/31/24

Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum

GlobeNewsWire • 05/22/24

Medicenna Provides Update on its Presentations at the 2024 ASCO Annual Meeting

GlobeNewsWire • 05/13/24

New Buy, Medicenna: Superkine Platform In Oncology

Seeking Alpha • 05/07/24

Medicenna Therapeutics Announces Closing of CA$20 Million Investment from RA Capital Management

GlobeNewsWire • 04/30/24

Medicenna Therapeutics Announces CA$20 Million Investment from RA Capital Management

GlobeNewsWire • 04/26/24

Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting

GlobeNewsWire • 04/24/24

Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewsWire • 04/10/24

Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)

GlobeNewsWire • 04/09/24